Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards

FDA clears Abbott's FreeStyle Libre 2 system in U.S. for adults and children (ages 4 and older) with diabetes, the only iCGM with unsurpassed 14-day accuracy that measures glucose every minute with optional real-time alarms.
/PRNewswire/ -- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA)

Voluntary Urgent Medical Device Correction Notice for FreeStyle Libre

2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes

Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards

New Diabetes Technology Coming in 2022

A Century of Diabetes Technology: Signals, Models, and Artificial Pancreas Control: Trends in Endocrinology & Metabolism

Monitoring Technologies- Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control - Endotext - NCBI Bookshelf

2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes

FreeStyle Libre 3: Guide to Cost and Functions - GoodRx

FreeStyle Libre 3: Guide to Cost and Functions - GoodRx

FreeStyle Libre 2 Continuous Glucose Monitor

Freestyle Libre 2 System, Continuous Glucose Monitoring

FreeStyle Libre 2 Sensor

Monitoring Technologies- Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control - Endotext - NCBI Bookshelf